Victor E. Velculescu

Assistant/Associate/Professor of Oncology and Pathology

Johns Hopkins University School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (70)

Purpose: Cancers present significant DNA methylation changes, which arise in a stochastic manner, marked by extensive epigenetic variation, indicative of high epigenetic instability. We aimed to evaluate the utility of epigenetic instability for cell-free DNA (cfDNA)-based cancer detection. Experimental Design: Through analysis of cancer DNA methylation datasets (n=2,084), we identified a set of 269 CGI regions that robustly captures this instability in a cancer-specific manner. We developed metrics to measure this epigenetic instability, termed the Epigenetic Instability Index (EII), for cancer screening via cfDNA methylation. Results: Machine learning classifiers employing the EII of these 269 regions efficiently identified breast and lung cancer from cfDNA, differentiating even stage IA LUAD with ~81% sensitivity and early-stage breast cancer with ~68% sensitivity, both at 95% specificity. Conclusion: Our studies demonstrate that quantifying epigenetic instability is a novel, capable approach to distinguishing cancer from normal cases using cfDNA, performing better than standard approaches using absolute methylation changes. The epigenetic instability-based approaches for cancer detection developed here, along with their validation in independent datasets, support further development and the potential for future clinical application of these strategies in cancer screening.

Year:

2026

Year:

2026

Background Epigenetic modulators may sensitize platinum-resistant ovarian cancer (PROC) to immune checkpoint inhibition by reprogramming the tumor microenvironment. Methods We report clinical and translational findings from a phase II non-randomized study of pembrolizumab and oral azacitidine in 34 women with PROC (NCT02900560). Key eligibility criteria included age 18 years or older, performance status of 0–1, measurable disease, platinum-resistant disease and histologically confirmed epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma. Primary endpoints included safety, tolerability, overall response rate (ORR) and disease control rate (DCR). Secondary endpoints included CA-125 response. The effect of combined epigenetic and immunotherapy was evaluated by transcriptomic analyses of 72 serially biopsied tumors. Results We show that the combination is moderately well tolerated and most common grade 3–4 adverse events are gastrointestinal side effects and anemia. ORR is 2.9% and DCR is 50%; with 3 of the 27 evaluable patients attaining a CA-125 response. Differential gene expression analyses reveal an upregulation of inflammatory and cytolytic genes and co-inhibitory checkpoints 6 weeks on-therapy. Upregulation of interferon signaling, antigen presentation and immune cell adhesion and migration gene sets are prominent on-therapy, together with an increase in density of CD8 + T-cells. Patients with a CA-125 and/or clinical response show an enrichment of adaptive and conserved immune response gene sets on-therapy. Conclusions Our findings highlight the potential of epigenetic modulators to re-shape the tumor microenvironment of PROC toward a more inflammed phenotype and may point to approaches to augment immunotherapy response.

Year:

2026

Year:

2025

Year:

2025

Supplementary Table S1 shows Clinical information of US/EU patients analyzed. Supplementary Table S2 is a summary of whole genome cfDNA analyses. Supplementary Table S3 shows clinical information of Hong Kong patients analyzed. Supplementary Table S4 shows the lowest scoring transcription factors in US/EU cohort samples. Supplementary Table S5 lists the plasma volume and cfDNA amounts used in genomic libraries.

Year:

2025

Supplementary Figure S1 shows contributions of individual genomic regions to the final trained DELFI surveillance model. Supplementary Figure S2 shows DELFI scores in individuals without cancer by age and sex. Supplementary Figure S3 shows DELFI scores in high-risk individuals without cancer across racial or ethnic groups. Supplementary Figure S4 shows DELFI scores in cirrhotic patients in relation to severity. Supplementary Figure S5 shows DELFI scores in individuals in relation to BMI. Supplementary Figure S6 Shows Performance of alternative DELFI models. Supplementary Figure S7 shows Correlation between rank ordered DELFI. Supplementary Figure S8 shows DELFI scores in patients with HCC were related to tumor characteristics. Supplementary Figure S9 shows DELFI scores in by etiology of underlying liver disease. Supplementary Figure S10 shows the DELFI score in patients with HCC is correlated to AFP levels. Supplementary Figure S11 shows the correlation of fragmentation profiles. Supplementary Figure S12 shows Genome wide fragmentation profiles in the Hong Kong validation cohort Supplementary Figure S13 shows chromosomal copy number in Hong Kong cohort. Supplementary Figure S14 shows the implementation of DELFI in liver cancer screening.

Year:

2025

(A) Genome-wide log2 copy ratios derived from targeted error-correction sequencing (TEC-Seq) data using CNVkit (Methods) are shown for each plasma sample, with copy number gains indicated in red and losses indicated in blue. Each row corresponds to a single plasma sample and rows are ordered with respect to consecutive sampling timepoints analyzed for each patient. (B-F) Genome-wide copy number profiles are shown for patients with matched tumor (WES) and plasma samples analyzed. We observed a high concordance between copy number profiles derived by whole exome sequencing, our approach (CNVkit) and ichorCNA for patients with detectable aneuploidy in plasma. (B) Patient 3 had undetectable ctDNA according to tumor-specific sequence alterations. However, this patient was classified as a molecular responder based on decrease of plasma aneuploidy to normal ploidy by the week 8 timepoint. (C) Patient 5 was classified as a molecular progressor based on the presence of tumor-specific sequence alterations and plasma aneuploidy across all timepoints analyzed. (D) Similarly, patient 9 was classified as a molecular progressor based on the persistence of mutations and plasma aneuploidy, which were detectable across all sampled timepoints from this patient. (E, F) Plasma copy number profiles for patients 11 and 14 indicated ploidy close to normal ploidy across all timepoints analyzed. These patients were classified as molecular responders based on tumor-derived sequence alterations.

Year:

2025

(A) PA scores were assessed across sequenced plasma (n=139) and matched white blood cell (n=32) samples from patients analyzed in the study cohort to determine a threshold for determination of aneuploidy in plasma. A PA score of 4.90, which was the maximum score observed in WBC DNA samples, was selected as the threshold for determination of aneuploidy in plasma. (B) Distribution of PA scores in the panel of 32 matched normal WBC samples analyzed for this study and an independent held out set of 56 WBC normal samples that were processed and analyzed using the same targeted panel and sequencing approach (Methods). The maximum PA score observed for both normal panels was 4.90, supporting the use of this value as the threshold for determination of aneuploidy in plasma. No significant differences were observed in the median PA score (indicated by dotted lines) for each normal panel. (C) Comparison between plasma aneuploidy scores and tumor fraction scores determined using an orthogonal method (ichorCNA) in matched normal DNA (blue) and plasma samples from all timepoints (yellow), plasma samples with detectable tumor-derived sequence mutations (orange) and plasma timepoints with undetectable sequence alterations (grey). Non-zero ichorCNA tumor fraction values were assigned to most samples resulting in significant overlap between the distributions of tumor fractions in plasma and matched normal DNA samples. In contrast, comparisons performed using plasma aneuploidy scores revealed significant differences in the distribution of assigned values across matched normal DNA samples (reflecting normal ploidy) and plasma samples (reflecting tumor aneuploidy). (D-I) Statistical modelling of MAF dynamics was performed using a set of known tumor-specific mutations previously characterized in Phallen et al, Science Transl Med, 2017 from a mixture of DNA from tumor cell lines spiked into unrelated wild-type DNA at dilutions ranging from 0.1-100%. Mutations in this set with replicate data were evaluated for (D, G) variability in MAF estimate followed by (E, H) calculation of the coefficient of variation (CV), and (F, I) finally projection of the relative percentage uncertainty in the MAF estimate. Analyses of mutation data from Phallen et al (2017) are shown in (D-F) and results from a simulation study of 30 mutations ranging in MAF from 0.1% to 80% using a simple statistical model of variability are shown in (G-I). Both analyses of mutation data from Phallen et al (2017) and simulation data showed a significant increase in CV as MAF decreases. For example, given a maximal MAF of 1%, the real 95% uncertainty in MAF estimate was shown to range from -50% to 50% (0.5% MAF to 1.5% MAF). Thus, a greater relative reduction is required to determine elimination of ctDNA for lower maximal MAF values. Based on these results, complete elimination of cell-free tumor load (to either 0% max MAF or undetectable PA) was deemed to be the most appropriate threshold for precise determination of molecular response.

Year:

2025

Longitudinal changes in cfTL were re-analyzed for each patient, considering all plasma variants independent of origin. Survival analyses revealed that CH-unfiltered ctDNA responses were not associated with either (A) overall survival-OS or (B) progression-free survival-PFS. Comparison between CH-unfiltered ctDNA responses and radiographic assessments (PR/CR vs SD/PD/MR) in these patients revealed that CH-unfiltered responses we not predictive of (C) OS at 12 and (D) 36 months, and PFS at (E) 3 and (F) 12 months, compared to best overall radiographic responses.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (39)

Jillian Phallen

Johns Hopkins University School of Medicine

UNITED STATES
View details

Jarushka Naidoo

Honorary Senior Lecturer

Royal College of Surgeons in Ireland

IRELAND
View details

Ernst Lengyel

University of Chicago

UNITED STATES
View details

Susan Domchek

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Gerrit Meijer

Professor of Oncologic Pathology

University Medical Center Groningen

NETHERLANDS
View details

Ernest Bobeff

Assistant Professor

Medical University of Lodz

POLAND
View details

Ali Zaidi

Associate Professor of Surgery / Medical Director Research

-

UNITED STATES
View details

Nita Ahuja

Chair of Surgery

Yale University

UNITED STATES
View details

Gary L Gallia

Johns Hopkins University

UNITED STATES
View details

Dimitrios Mathios

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

Nichole Tanner

Professor of Medicine

Medical University of South Carolina

UNITED STATES
View details

Wade T. Iams

-

UNITED STATES
View details

Fabien Maldonado

Vanderbilt University

UNITED STATES
View details

Judy Huang

Professor & Vice Chair

Johns Hopkins University School of Medicine

UNITED STATES
View details

Christopher Cann

Assistant Professor

Fox Chase Cancer Center

UNITED STATES
View details

Vincent K. Lam

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Chul-Kee Park

Professor

Seoul National University College of Medicine

SOUTH KOREA
View details

Christina Therkildsen

Research group leader

Copenhagen University Hospital

DENMARK
View details

Kim Monkhorst

The Netherlands Cancer Institute

NETHERLANDS
View details

Dennis J. Slamon

University of California, Los Angeles

UNITED STATES
View details

Tian-Li Wang

Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Debraj Mukherjee

Faculty

Johns Hopkins University School of Medicine

UNITED STATES
View details

Anil Vachani

Associate Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Jenna Canzoniero

Assistant Professor - Women's Malignancies Program

Johns Hopkins University School of Medicine

UNITED STATES
View details

Manmeet Singh Ahluwalia

Professor of Translational Medicine

Florida International University Herbert Wertheim College of Medicine

UNITED STATES
View details

Christine Lovly

Professor and Division Chief, Thoracic Medical Oncology

Beckman Research Institute, City of Hope

UNITED STATES
View details

Remond J.A. Fijneman

Principal Investigator

The Netherlands Cancer Institute

NETHERLANDS
View details

Claus Lindbjerg Andersen

VIP, Professor

Aarhus University

DENMARK
View details

Valsamo Anagnostou

Alex Grass Professor of Oncology

Johns Hopkins University School of Medicine

UNITED STATES
View details

Ie-Ming Shih

Professor

Johns Hopkins University

UNITED STATES
View details

Thomas Pisanic

Associate Research Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Beatriz Carvalho

Senior scientist

The Netherlands Cancer Institute

NETHERLANDS
View details

Nicholas Dracopoli

Chief Scientific Officer

-

UNITED STATES
View details

Ronny Drapkin

Franklin Payne Professor of Pathology in Obstetrics and Gynecology

University of Pennsylvania

UNITED STATES
View details

Hariharan Easwaran

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Patrick M. Forde

Trinity College Dublin

IRELAND
View details

Kwok-Kin Wong

NYU Langone Medical Center

UNITED STATES
View details

Robert B Scharpf

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Jing Sun

Associate Research Professor

Johns Hopkins University

UNITED STATES
View details